Thus, our study positions PRAJA1, along with its downstream targets like p-eEF2, spinophilin, and L-VGCCs, as a compelling therapeutic target for cognitive enhancement in AD and potentially other neurological disorders [40]. Here, PPP1R9B is linked to nervous system disorder.